LIVE SESSION BRIEF Medical Devices $8M Cap Quant: HOLD

Biomerica Inc (BMRA) — Live Session & Technical Brief

Updated Nov 16, 2026 2:42 PM ET · Prev Close $1.36

Pro Workspace
Last Session Price
$1.36 +0.00%
+$0.00 vs $1.36 prior close
Intraday Range
$1.36 – $1.39
Open $1.39
Relative Volume
0.70x Avg
6,924 sh
52-Week Range
$1.27 – $2.94
Benchmark Alpha
+1.89% vs SPY
+2.42% vs QQQ
20-Session Trend -20.9%

Session Regime & Catalyst Assessment

64% Signal Conviction
TECHNICAL 64% Driver Weight

Controlled Session Consolidation (+0.00%) in Medical Devices

Biomerica Inc (BMRA) is trading within a tight intraday band at $1.36 (+0.00%, 0.70x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, BMRA is outperforming the S&P 500 by +1.89%. 14-day RSI stands at 28.0, keeping momentum in a oversold regime.

NEWS 70% Weight
Biomerica Reports First Quarter Fiscal 2027 Financial Results

InFoods IBS Commercial Progress Medicare-related test orders increased 120 in September 2026 compared to August, with growing physician participation and repeat ordering activityInFoods IBS update 100 of all initial vali

TECHNICAL 68% Weight
Moving Average Structure: Bearish Alignment

Price ($1.36) trades relative to 20-day SMA ($1.62) and 50-day SMA ($1.96).

Volume Confirmation
LOW VOLUME (0.70x) Consolidation
Sub-average participation — monitor RVOL expansion above 1.2x.
Composite Catalyst Confidence 64%
Cross-checked across volume tape, benchmark alpha, options flow, and news.

Market & Sector Relative Strength

BMRA outperforming the S&P 500 by +1.89%
BMRA Session
+0.00%
$1.36
S&P 500 (SPY)
-1.89%
$740.11
Nasdaq 100 (QQQ)
-2.42%
$663.44
Healthcare (XLV)
-0.38%
$188.14
Alpha vs SPY: +1.89% Alpha vs QQQ: +2.42% Alpha vs XLV: +0.38%

Recent BMRA Catalyst Headlines

Verified Wire
Biomerica Reports First Quarter Fiscal 2027 Financial Results

InFoods IBS Commercial Progress Medicare-related test orders increased 120 in September 2026 compared to August, with growing physician participation and repeat ordering activityInFoods IBS update 100 of all initial vali

Yahoo Finance · Oct 16, 2026
Biomerica Reports Fiscal 2026 Year-End Financial Results

Fiscal 2026 fourth quarter net sales increased approximately 17 compared to the fourth quarter of fiscal 2025Full-year net loss improved by approximately 24 to approximately 3.8 millionInFoods IBS update 100 of all initi

Yahoo Finance · Sep 01, 2026
Biomerica Announces 2.23 Million Financing

Financing priced at 1.60 with no warrants or discountB. Riley Principal Capital and B. Riley executives, as well as Biomerica's CEO and all members of Biomerica s Board of Directors participated in the financingProceeds

Yahoo Finance · Aug 27, 2026

1–3 Day Expected Range & Key Level

48% Follow-Through
Lower Bound
$1.33
Short-term support band
Upper Bound
$1.39
Short-term resistance band
Key Inflection Level
$1.39 (session resistance)

Monitor volume expansion above 1.5x RVOL around $1.39 (session resistance) for directional breakout confirmation.

Technical Regime (BMRA)

BEARISH MA TREND
RSI (14)
28.0
Oversold
20-Day SMA
$1.62
Below 20d
50-Day SMA
$1.96
Below 50d
MACD Signal
Bearish
MACD -0.14
ADX (14)
27.0
Strong trend
10d Momentum
-0.37
Soft 10-day momentum

Retail & Crowd Sentiment

Bearish
24h Messages
0
7d avg 0.0
Bullish / Bearish
0.0% / 0.0%
None buzz
Crowd Discussion Digest

Biomerica, Inc. ($BMRA) announced a contract-development agreement with initial target fees exceeding $1.75 million. The work is expected to utilize existing facilities and staff.

Reddit communities: 1 comment (Bearish)

About Biomerica Inc

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which …

Sector
Healthcare
Market Cap
$8M
Employees
54

Get Instant BMRA Catalyst Alerts

Receive an email alert when BMRA triggers an unusual volume breakout, options sweep, or rating shift.

Other Liquid Stocks Moving Today

All Today's Movers

BMRA Session & Catalyst FAQ

Why is BMRA stock trading near flat today?

Biomerica Inc (BMRA) is trading within a tight intraday band at $1.36 (+0.00%, 0.70x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, BMRA is outperforming the S&P 500 by +1.89%. 14-day RSI stands at 28.0, keeping momentum in a oversold regime.

Is BMRA stock a buy or sell right now?

Today's session carries a 64% catalyst conviction score on 0.70x relative volume (low participation). Our multi-factor model currently rates BMRA as HOLD. Review full valuation, quality, and timing signals on the BMRA Buy or Sell Decision Brief →

What is BMRA's intrinsic value and expected trading range?

At $1.36, BMRA's modeled 1-to-3 session range is $1.33 – $1.39, with a key inflection level at $1.39 (session resistance). Compare current price against multi-year cash flow projections in the BMRA Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →

What do RSI and moving averages signal for BMRA?

RSI at 28.0 indicates oversold conditions — watch for mean-reversion support. BMRA trades at $1.36 relative to its 20-day SMA ($1.62) and 50-day SMA ($1.96), reflecting a bearish moving-average structure.

Tradestie Flagship Research & Market Hubs